Reprogramming of glucose metabolism in pancreatic cancer: mechanisms, implications, and therapeutic perspectives
Authors:
Open Access
- 24 June 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1586959
Abstract
As a typical pathological feature of pancreatic ductal adenocarcinoma, reprogramming of glucose metabolism synergistically drives the tumorigenesis and development process through molecular mechanisms such as regulating the expression of driver genes, modifying key functional proteins, triggering mitochondrial metabolism abnormality, and remodeling the tumor microenvironment. It is worth noting that this metabolic remodeling phenomenon is significantly associated with the formation of chemoresistance. Based on the latest research progress, this paper systematically describes the molecular basis of glucose metabolic reprogramming in pancreatic cancer, drug resistance characteristics and its targeted intervention strategies, and provides a theoretical framework for the research and development of innovative drugs.Keywords
This publication has 184 references indexed in Scilit:
- Circular RNA LIPH promotes pancreatic cancer glycolysis and progression through sponge miR-769-3p and interaction with GOLM1Clinical and Translational Medicine, 2024
- Vitamin‐C‐dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrestMolecular Oncology, 2024
- Metabolomic Investigations into Hypoxia-Mediated Metabolic Reprogramming of Pancreatic Cancer Cells2024
- Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progressionClinical and Translational Medicine, 2021
- SLC45A4 promotes glycolysis and prevents AMPK/ULK1‐induced autophagy in TP53 mutant pancreatic ductal adenocarcinomaThe Journal of Gene Medicine, 2021
- SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A–c‐Myc axisMolecular Oncology, 2021
- Mitochondrial dynamics as regulators of cancer biologyCellular and Molecular Life Sciences, 2017
- A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2012
- Regulation of mitochondrial dynamics: convergences and divergences between yeast and vertebratesCellular and Molecular Life Sciences, 2012
- Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of CancerCellular and Molecular Life Sciences, 2008